UNSPSC 51312107: Lodoxamide tromethamine

This classification denotes a mast cell stabilizer, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50LV9A548L. European Medicines Agency schedules Lodoxamide trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02964MIG. Lodoxamide tromethamine generally arises in the molecular formula C11H6CLN3O6.2C4H11NO3. The term 'lodoxamide tromethamine' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule lodoxamide tromethamine under HS 29269095 and SITC 51484. As of Q4 2014, LODOXAMIDE TROMETHAMINE remains US FDA's Preferred Term for this commodity. Lodoxamide tromethamine bears US NLM identifiers UMLS ID C0065148 and NCI Concept Code C29160. SMILES: C1C(CC(C(C1NC(=O)C(=O)O)CL)NC(=O)C(=O)O)C#N.C(C(CO)(CO)N)O.C(C(CO)(CO)N)O.

UNSPSC 51312107 Lodoxamide tromethamine is a Commodity code that shows minimal alignment with recent state and local procurement activity. The recent opportunity tagged to this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—is a public-health supply procurement for opioid-reversal medication and harm-reduction equipment, not the ophthalmic antihistamine that the code nominally describes. State and local governments do procure pharmaceutical products under related UNSPSC families, but this particular code does not reflect current buying patterns in the opportunities data.

Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a response deadline of July 26, 2023. Vendors must include shipping and delivery costs in bids, hold required insurance coverage, and pass E-Verify compliance. The contract carries a two-year initial term with a one-year renewal option and may be funded through FEMA, introducing federal compliance requirements. The mismatch between the code's pharmaceutical scope and the actual procurement suggests the opportunity may have been miscoded; practitioners pursuing state and local pharmaceutical or medical-supply contracts should verify the correct UNSPSC family or class codes for naloxone and related public-health supplies rather than relying on this commodity classification.